{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:26:14Z","timestamp":1788492374826,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00125-023-06015-1","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:01:34Z","timestamp":1696586494000},"page":"3-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-1822","authenticated-orcid":false,"given":"Vikas S.","family":"Sridhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine P.","family":"Limonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Skyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"6015_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCH et al (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102:S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"6015_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2337\/dci17-0047","volume":"41","author":"GL Bakris","year":"2018","unstructured":"Bakris GL, Molitch M (2018) Are all patients with type 1 diabetes destined for dialysis if they live long enough? Probably not. Diabetes Care 41:389\u2013390. https:\/\/doi.org\/10.2337\/dci17-0047","journal-title":"Diabetes Care"},{"issue":"12","key":"6015_CR3","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s13300-021-01169-w","volume":"12","author":"M Dena","year":"2021","unstructured":"Dena M, Svensson AM, Olofsson KE et al (2021) Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes. Diabetes Ther 12(12):3093\u20133105. https:\/\/doi.org\/10.1007\/s13300-021-01169-w","journal-title":"Diabetes Ther"},{"key":"6015_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S2213-8587(22)00099-7","volume":"10","author":"F Jansson Sigfrids","year":"2022","unstructured":"Jansson Sigfrids F, Groop PH, Harjutsalo V (2022) Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0\u201314 years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol 10:489\u2013498. https:\/\/doi.org\/10.1016\/S2213-8587(22)00099-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6015_CR5","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.2337\/dc22-0926","volume":"45","author":"J Halminen","year":"2022","unstructured":"Halminen J, Sattaer N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes. Diabetes Care 45:2326\u20132335. https:\/\/doi.org\/10.2337\/dc22-0926","journal-title":"Diabetes Care"},{"key":"6015_CR6","doi-asserted-by":"publisher","first-page":"204201881986322","DOI":"10.1177\/2042018819863226","volume":"10","author":"L Graves","year":"2019","unstructured":"Graves L, Donaghue K (2019) Management of diabetes complications in youth. Ther Adv Endocrinol Metab 10:2042018819863226. https:\/\/doi.org\/10.1177\/2042018819863226","journal-title":"Ther Adv Endocrinol Metab"},{"key":"6015_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc20-2839","volume":"44","author":"R Kristofi","year":"2021","unstructured":"Kristofi R, Bodegard J, Norhammar A et al (2021) Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study. Diabetes Care 44:1211\u20131218. https:\/\/doi.org\/10.2337\/dc20-2839","journal-title":"Diabetes Care"},{"key":"6015_CR8","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","volume":"138","author":"DA McAllister","year":"2018","unstructured":"McAllister DA, Read SH, Kerssens J et al (2018) Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation 138:2774\u20132786. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034986","journal-title":"Circulation"},{"key":"6015_CR9","doi-asserted-by":"publisher","first-page":"e165654","DOI":"10.1172\/JCI165654","volume":"133","author":"S Mohandes","year":"2023","unstructured":"Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K (2023) Molecular pathways that drive diabetic kidney disease. J Clin Invest 133:e165654. https:\/\/doi.org\/10.1172\/JCI165654","journal-title":"J Clin Invest"},{"key":"6015_CR10","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1113\/jphysiol.2014.272328","volume":"592","author":"C Mora-Fern\u00e1ndez","year":"2014","unstructured":"Mora-Fern\u00e1ndez C, Dominguez-Pimentel V, Muros de Fuentes M, Gorriz JL, Martinez-Castelao A, Navarro-Gonzalez JF (2014) Diabetic kidney disease: from physiology to therapeutics. J Physiol 592:3997\u20134009. https:\/\/doi.org\/10.1113\/jphysiol.2014.272328","journal-title":"J Physiol"},{"key":"6015_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2018.9","volume":"14","author":"JM Forbes","year":"2018","unstructured":"Forbes JM, Thorburn DR (2018) Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 14:291\u2013312. https:\/\/doi.org\/10.1038\/nrneph.2018.9","journal-title":"Nat Rev Nephrol"},{"key":"6015_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.semnephrol.2007.01.006","volume":"27","author":"ALY Tan","year":"2007","unstructured":"Tan ALY, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130\u2013143. https:\/\/doi.org\/10.1016\/j.semnephrol.2007.01.006","journal-title":"Semin Nephrol"},{"key":"6015_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","volume":"16","author":"G Giacchetti","year":"2005","unstructured":"Giacchetti G, Sechi LA, Rilli S, Carey RM (2005) The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16:120\u2013126. https:\/\/doi.org\/10.1016\/j.tem.2005.02.003","journal-title":"Trends Endocrinol Metab"},{"issue":"Suppl 77","key":"6015_CR14","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1046\/j.1523-1755.2000.07715.x","volume":"58","author":"DJ Leehey","year":"2000","unstructured":"Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 58(Suppl 77):S93-98. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.07715.x","journal-title":"Kidney Int Suppl"},{"key":"6015_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11892-019-1123-8","volume":"19","author":"Y Lytvyn","year":"2019","unstructured":"Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ (2019) Mineralocorticoid antagonism and diabetic kidney disease. Curr Diab Rep 19:4. https:\/\/doi.org\/10.1007\/s11892-019-1123-8","journal-title":"Curr Diab Rep"},{"key":"6015_CR16","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2023) 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care 46:S158\u2013S190. https:\/\/doi.org\/10.2337\/dc23-S010","journal-title":"Diabetes Care"},{"key":"6015_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/jama.287.19.2563","volume":"287","author":"Writing Team for the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group","year":"2002","unstructured":"Writing Team for the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:99\u2013111. https:\/\/doi.org\/10.1001\/jama.287.19.2563","journal-title":"JAMA"},{"key":"6015_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2337\/dc13-2113","volume":"37","author":"IH de Boer","year":"2014","unstructured":"de Boer IH, DCCT\/EDIC Research Group (2014) Kidney disease and related findings in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 37:24\u201330. https:\/\/doi.org\/10.2337\/dc13-2113","journal-title":"Diabetes Care"},{"issue":"20","key":"6015_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"E Lewis","year":"1993","unstructured":"Lewis E, Hunsicker L, Bain R, Rohde R (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng J Med 329(20):1456\u20131462. https:\/\/doi.org\/10.1056\/NEJM199311113292004","journal-title":"N Eng J Med"},{"key":"6015_CR20","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","volume":"349","author":"EUCLID Study Group","year":"1997","unstructured":"EUCLID Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787\u20131792. https:\/\/doi.org\/10.1016\/S0140-6736(96)10244-0","journal-title":"Lancet"},{"key":"6015_CR21","doi-asserted-by":"publisher","first-page":"CD006257","DOI":"10.1002\/14651858.CD006257","volume":"4","author":"GFM Strippoli","year":"2006","unstructured":"Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 4:CD006257. https:\/\/doi.org\/10.1002\/14651858.CD006257","journal-title":"Cochrane Database Syst Rev"},{"key":"6015_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes (RASS). N Engl J Med 361:40\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0808400","journal-title":"N Engl J Med"},{"key":"6015_CR23","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C et al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382:2493\u20132503. https:\/\/doi.org\/10.1056\/NEJMoa1916624","journal-title":"N Engl J Med"},{"key":"6015_CR24","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2023) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023. Diabetes Care 46:S140\u2013S157. https:\/\/doi.org\/10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"key":"6015_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13300-022-01277-1","volume":"13","author":"M Botana","year":"2022","unstructured":"Botana M, Escalada J, Merchante \u00c1, Reyes R, Rozas P (2022) Prevention of cardiorenal complications with sodium\u2013glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther 13:5\u201317. https:\/\/doi.org\/10.1007\/s13300-022-01277-1","journal-title":"Diabetes Ther"},{"key":"6015_CR26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"6015_CR27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"6015_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"6015_CR29","doi-asserted-by":"publisher","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","volume":"126","author":"H Liu","year":"2022","unstructured":"Liu H, Sridhar VS, Boulet J et al (2022) Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism 126:154918. https:\/\/doi.org\/10.1016\/j.metabol.2021.154918","journal-title":"Metabolism"},{"key":"6015_CR30","doi-asserted-by":"publisher","first-page":"100895","DOI":"10.1016\/j.eclinm.2021.100895","volume":"37","author":"JC Laursen","year":"2021","unstructured":"Laursen JC, Sondergaard-Heinrich N, Lopes de Melo JM et al (2021) Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. eClinicalMedicine 37:100895. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100895","journal-title":"eClinicalMedicine"},{"issue":"5","key":"6015_CR31","doi-asserted-by":"publisher","first-page":"e164486","DOI":"10.1172\/JCI164486","volume":"133","author":"JA Schaub","year":"2023","unstructured":"Schaub JA, AlAkwaa FM, McCown PJ et al (2023) SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth onset type 2 diabetes. J Clin Invest 133(5):e164486. https:\/\/doi.org\/10.1172\/JCI164486","journal-title":"J Clin Invest"},{"key":"6015_CR32","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, Emberson JR, Haynes R et al (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"6015_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/dom.14127","volume":"22","author":"HW Rodbard","year":"2020","unstructured":"Rodbard HW, Giaccari A, Lajara R et al (2020) Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. Diabetes Obes Metab 22:2089\u20132096. https:\/\/doi.org\/10.1111\/dom.14127","journal-title":"Diabetes Obes Metab"},{"key":"6015_CR34","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, Henry RR, Banks P et al (2017) Effects of Sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377:2337\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa1708337","journal-title":"N Engl J Med"},{"key":"6015_CR35","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM et al (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41:2560\u20132569. https:\/\/doi.org\/10.2337\/dc18-1749","journal-title":"Diabetes Care"},{"key":"6015_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.14248","volume":"23","author":"M Phillip","year":"2021","unstructured":"Phillip M, Mathieu C, Lind M et al (2021) Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. Diabetes Obes Metab 23:549\u2013560. https:\/\/doi.org\/10.1111\/dom.14248","journal-title":"Diabetes Obes Metab"},{"key":"6015_CR37","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2337\/dc19-0937","volume":"42","author":"DH van Raalte","year":"2019","unstructured":"van Raalte DH, Bjornstad P, Persson F et al (2019) The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes. Diabetes Care 42:1921\u20131929. https:\/\/doi.org\/10.2337\/dc19-0937","journal-title":"Diabetes Care"},{"key":"6015_CR38","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.07700621","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Bjornstad P, Perkins BA et al (2021) Kidney effects of empagliflozin in people with type 1 diabetes. Clin J Am Soc Nephrol 16:1715\u20131719. https:\/\/doi.org\/10.2215\/CJN.07700621","journal-title":"Clin J Am Soc Nephrol"},{"key":"6015_CR39","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","volume":"8","author":"PH Groop","year":"2020","unstructured":"Groop PH, Dandona P, Phillip M et al (2020) Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol 8:845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(20)30280-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6015_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Woodward M, Perkovic V et al (2020) Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail 8:57\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2019.08.004","journal-title":"JACC Heart Fail"},{"key":"6015_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li J, Neal B, Perkovic V et al (2020) Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int 98:769\u2013777. https:\/\/doi.org\/10.1016\/j.kint.2020.04.051","journal-title":"Kidney Int"},{"key":"6015_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc21-1584","volume":"45","author":"A Palanca","year":"2022","unstructured":"Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience. Diabetes Care 45:650\u2013658. https:\/\/doi.org\/10.2337\/dc21-1584","journal-title":"Diabetes Care"},{"issue":"7","key":"6015_CR43","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/dom.15047","volume":"25","author":"EB Stougaard","year":"2023","unstructured":"Stougaard EB, Rossing P, Vistisen D et al (2023) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes. Diabetes Obes Metab 25(7):1874\u20131882. https:\/\/doi.org\/10.1111\/dom.15047","journal-title":"Diabetes Obes Metab"},{"key":"6015_CR44","doi-asserted-by":"publisher","first-page":"e1003461","DOI":"10.1371\/journal.pmed.1003461","volume":"17","author":"G Musso","year":"2020","unstructured":"Musso G, Sircana A, Saba F, Cassader M, Gambino R (2020) Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression. PLOS Med 17:e1003461. https:\/\/doi.org\/10.1371\/journal.pmed.1003461","journal-title":"PLOS Med"},{"key":"6015_CR45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42:1147\u20131154. https:\/\/doi.org\/10.2337\/dc18-2316","journal-title":"Diabetes Care"},{"key":"6015_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11892-022-01471-2","volume":"22","author":"H Liu","year":"2022","unstructured":"Liu H, Sridhar VS, Perkins BA, Rosenstock J, Cherney DZI (2022) SGLT2 inhibition in type 1 diabetes with diabetic kidney disease: potential cardiorenal benefits can outweigh preventable risk of diabetic ketoacidosis. Curr Diab Rep 22:317\u2013332. https:\/\/doi.org\/10.1007\/s11892-022-01471-2","journal-title":"Curr Diab Rep"},{"key":"6015_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1210\/clinem\/dgz003","volume":"105","author":"M Thomas","year":"2020","unstructured":"Thomas M, Harjutsalo V, Feodoroff M et al (2020) The long-term incidence of hospitalization for ketoacidosis in adults with established T1D-a prospective cohort study. J Clin Endocrinol Metab 105:231\u2013241. https:\/\/doi.org\/10.1210\/clinem\/dgz003","journal-title":"J Clin Endocrinol Metab"},{"key":"6015_CR48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653\u2013662. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6015_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris G et al (2022) Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145:575\u2013585. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055459","journal-title":"Circulation"},{"key":"6015_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad009","author":"P Rossing","year":"2023","unstructured":"Rossing P, Baeres FMM, Bakris G et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfad009","journal-title":"Nephrol Dial Transplant"},{"key":"6015_CR51","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","volume":"54","author":"R Kodera","year":"2011","unstructured":"Kodera R, Shikata K, Kataoka HU et al (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965\u2013978. https:\/\/doi.org\/10.1007\/s00125-010-2028-x","journal-title":"Diabetologia"},{"key":"6015_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ajpath.2012.09.016","volume":"182","author":"A Ojima","year":"2013","unstructured":"Ojima A, Ishibashi Y, Matsui T et al (2013) Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 182:132\u2013141. https:\/\/doi.org\/10.1016\/j.ajpath.2012.09.016","journal-title":"Am J Pathol"},{"key":"6015_CR53","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU et al (2016) Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial. Diabetes Care 39:1702\u20131710. https:\/\/doi.org\/10.2337\/dc16-0691","journal-title":"Diabetes Care"},{"key":"6015_CR54","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahren","year":"2016","unstructured":"Ahren B, Hirsch IB, Pieber TR et al (2016) Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial. Diabetes Care 39:1693\u20131701. https:\/\/doi.org\/10.2337\/dc16-0690","journal-title":"Diabetes Care"},{"key":"6015_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1573399815666190614141918","volume":"16","author":"P Dimitrios","year":"2020","unstructured":"Dimitrios P, Doumas M, Vasilios K et al (2020) Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis. Curr Diabetes Rev 16:313\u2013326. https:\/\/doi.org\/10.2174\/1573399815666190614141918","journal-title":"Curr Diabetes Rev"},{"key":"6015_CR56","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","volume":"8","author":"JFE Mann","year":"2020","unstructured":"Mann JFE, Hansen T, Idorn T et al (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1\u20137 randomised controlled trials. Lancet Diabetes Endocrinol 8:880\u2013893. https:\/\/doi.org\/10.1016\/S2213-8587(20)30313-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6015_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"6015_CR58","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I et al (2022) Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10:774\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(22)00243-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6015_CR59","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Frias JP et al (2023) Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N Engl J Med 389:514\u2013526. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"6015_CR60","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM et al (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402:529\u2013544. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X","journal-title":"Lancet"},{"issue":"18","key":"6015_CR61","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"6015_CR62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1464-5491.2012.03585.x","volume":"29","author":"SE Nielsen","year":"2012","unstructured":"Nielsen SE, Persson F, Frandsen E et al (2012) Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 29:184\u2013190. https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03585.x","journal-title":"Diabet Med"},{"key":"6015_CR63","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR et al (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68:2829\u20132836. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00756.x","journal-title":"Kidney Int"},{"key":"6015_CR64","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR et al (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70:536\u2013542. https:\/\/doi.org\/10.1038\/sj.ki.5001580","journal-title":"Kidney Int"},{"key":"6015_CR65","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/ndt\/gfp311","volume":"24","author":"KJ Schjoedt","year":"2009","unstructured":"Schjoedt KJ, Christensen PK, Jorsal A et al (2009) Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrol Dial Transplant 24:3343\u20133349. https:\/\/doi.org\/10.1093\/ndt\/gfp311","journal-title":"Nephrol Dial Transplant"},{"key":"6015_CR66","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","volume":"37","author":"J Hou","year":"2015","unstructured":"Hou J, Xiong W, Cao L, Wen X, Li A (2015) Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 37:2086-2103.e10. https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.508","journal-title":"Clin Ther"},{"key":"6015_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B (2017) Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol 243:271\u2013305. https:\/\/doi.org\/10.1007\/164_2016_76","journal-title":"Handb Exp Pharmacol"},{"key":"6015_CR68","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial. JAMA 314:884\u2013894. https:\/\/doi.org\/10.1001\/jama.2015.10081","journal-title":"JAMA"},{"key":"6015_CR69","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"6015_CR70","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"6015_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Filippatos G, Agarwal R et al (2022) Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep 7:36\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.008","journal-title":"Kidney Int Rep"},{"key":"6015_CR72","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dom.14883","volume":"25","author":"P Rossing","year":"2023","unstructured":"Rossing P, Agarwal R, Anker SD et al (2023) Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab 25:407\u2013416. https:\/\/doi.org\/10.1111\/dom.14883","journal-title":"Diabetes Obes Metab"},{"key":"6015_CR73","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42:152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"key":"6015_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504623","volume":"6","author":"R Raina","year":"2020","unstructured":"Raina R, Chauvin A, Chakraborty R et al (2020) The role of endothelin and endothelin antagonists in chronic kidney disease. Kidney Dis 6:22\u201334. https:\/\/doi.org\/10.1159\/000504623","journal-title":"Kidney Dis"},{"key":"6015_CR75","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL et al (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393:1937\u20131947. https:\/\/doi.org\/10.1016\/S0140-6736(19)30772-X","journal-title":"Lancet"},{"key":"6015_CR76","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nep.14130","volume":"28","author":"EYM Chung","year":"2023","unstructured":"Chung EYM, Badve SV, Heerspink HJL, Wong MG (2023) Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrology 28:97\u2013108. https:\/\/doi.org\/10.1111\/nep.14130","journal-title":"Nephrology"},{"key":"6015_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","volume":"78","author":"ES Buys","year":"2018","unstructured":"Buys ES, Zimmer DP, Chickering J et al (2018) Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide Biol Chem 78:72\u201380. https:\/\/doi.org\/10.1016\/j.niox.2018.05.009","journal-title":"Nitric Oxide Biol Chem"},{"key":"6015_CR78","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1152\/ajprenal.00280.2004","volume":"288","author":"B Hohenstein","year":"2005","unstructured":"Hohenstein B, Daniel C, Wagner A, Stasch JP, Hugo C (2005) Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. Am J Physiol Ren Physiol 288:685\u2013693. https:\/\/doi.org\/10.1152\/ajprenal.00280.2004","journal-title":"Am J Physiol Ren Physiol"},{"key":"6015_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2215\/CJN.08410520","volume":"16","author":"JP Hanrahan","year":"2021","unstructured":"Hanrahan JP, de Boer IH, Bakris GL et al (2021) Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial. Clin J Am Soc Nephrol 16:59\u201369. https:\/\/doi.org\/10.2215\/CJN.08410520","journal-title":"Clin J Am Soc Nephrol"},{"key":"6015_CR80","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"6015_CR81","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Everett BM et al (2018) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391:319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(17)32814-3","journal-title":"Lancet"},{"key":"6015_CR82","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","volume":"71","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Macfadyen JG, Glynn RJ et al (2018) Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405\u20132414. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.490","journal-title":"J Am Coll Cardiol"},{"key":"6015_CR83","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM et al (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397:2060\u20132069. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1","journal-title":"Lancet"},{"key":"6015_CR84","doi-asserted-by":"publisher","first-page":"105892","DOI":"10.1016\/j.cct.2019.105892","volume":"90","author":"AT Reutens","year":"2020","unstructured":"Reutens AT, Jandeleit-Dahm K, Thomas M et al (2020) A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1\/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations. Contemp Clin Trials 90:105892. https:\/\/doi.org\/10.1016\/j.cct.2019.105892","journal-title":"Contemp Clin Trials"},{"key":"6015_CR85","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/ndt\/gfac242","volume":"38","author":"M Nangaku","year":"2023","unstructured":"Nangaku M, Takama H, Ichikawa T et al (2023) Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol Dial Transplant 38:1204\u20131216. https:\/\/doi.org\/10.1093\/ndt\/gfac242","journal-title":"Nephrol Dial Transplant"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-06015-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T19:03:28Z","timestamp":1728155008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-06015-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6015"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-06015-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VSS is supported by a Department of Medicine Eliot Phillipson Clinician-Scientist Training Program, a Banting and Best Diabetes Centre Postdoctoral Fellowship at the University of Toronto and a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award. CPL is supported by an American Kidney Fund\u2019s Clinical Scientist in Nephrology Award. DZIC is supported by a Department of Medicine, University of Toronto Merit Award and receives support from the CIHR, Diabetes Canada and the Heart & Stroke\/Richard Lewar Centre of Excellence in Cardiovascular Research. DZIC is also the recipient of a 5 year CIHR\u2013Kidney Foundation of Canada Team Grant Award. PR is supported by a Novo Nordisk Foundation grant (NNF22OC0077730; \u2018Multifactorial intervention to reduce cardiorenal disease in type 1 diabetes \u2013 a prospective, randomised, open, multicenter study \u2013 the Steno 1 study\u2019). JSS is supported by the Diabetes Research Institute Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"VSS has received conference travel support from Merck. DZIC has received honoraria from Boehringer Ingelheim\u2013Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi Tanabe, AbbVie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim\u2013Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL Behring and Novo Nordisk. PR has received the following: consultancy and\/or speaking fees (to his institution) from AbbVie, Abbott, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk and Sanofi-Aventis, and research grants from AstraZeneca, Bayer and Novo Nordisk. REP has received consulting fees from Bayer, Corcept Therapeutics, Dexcom, Hanmi Pharmaceutical, Merck, Novo Nordisk, Pfizer, Sanofi, Scohia Pharma and Sun Pharmaceutical Industries, and grants\/research support from Hanmi Pharmaceutical, Janssen, Metavention, Novo Nordisk, Poxel and Sanofi. All funds are paid directly to REP\u2019s employer, AdventHealth, a non-profit organisation that supports education and research. JSS has been an advisor to 4Immune, Adocia, Altheia, Arecor, AstraZeneca, Avotres, Bayer, COUR, Cue Biopharma, Dance Biopharm\/Aerami, Diasome, Enthera, Imcyse, Immunomolecular Therapeutics, Kriya, Novo Nordisk, Oramed, Orgenesis, Precigen\/ActoBiotics, Provention Bio, Sanofi, Signos, Vertex and Viacyte. He is a member of the Board of Directors of Dexcom and Applied Therapeutics. He is Chair of the Strategic Advisory Board of the EU INNODIA consortium. P-HG has received lecture fees from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi and Sciarc. He is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestl\u00e9, Novartis, Novo Nordisk and Sanofi. CPL declares that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"VSS, CPL, P-HG, HJLH, REP, PR, JSS and DZIC conceived and designed the manuscript; VSS, CPL and DZIC drafted the paper; VSS, CPL, P-HG, HJLH, REP, PR, JSS and\u00a0DZIC performed critical revision. All authors approved the final version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}